IP83-26: Real-world treatment patterns and survival outcomes in metastatic urothelial carcinoma in the enfortumab vedotin era: impact of first-line enfortumab vedotin plus pembrolizumab versus platinum chemotherapy

IP83-26: Real-world treatment patterns and survival outcomes in metastatic urothelial carcinoma in the enfortumab vedotin era: impact of first-line enfortumab vedotin plus pembrolizumab versus platinum chemotherapy

Monday, May 18, 2026 9:30 AM to 11:30 AM · 1 hr. 59 min. (America/New_York)
147A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!